162 results
8-K
EX-99.1
REGN
Regeneron Pharmaceuticals, Inc.
2 May 24
Regeneron Reports First Quarter 2024 Financial and Operating Results
7:06am
, or regulatory approval; ongoing regulatory obligations and oversight impacting Regeneron's Products, research and clinical programs, and business
8-K
EX-99.1
REGN
Regeneron Pharmaceuticals, Inc.
2 Feb 24
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
7:16am
obligations and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient privacy
8-K
EX-99.1
eqqkf 5zw7lvm
8 Jan 24
2 Strategy & Business Update J.P.Morgan Healthcare Conference 2024 Co - Founder, Board Co - Chair, President & Chief Executive Officer
6:30am
8-K
EX-99.1
u66 2l4yb
2 Nov 23
Regeneron Reports Third Quarter 2023 Financial and Operating Results
7:10am
SC TO-T
EX-99
1nj4gvln3mtsw sq13qn
25 Aug 23
Third party tender offer statement
7:46am
8-K
EX-99.1
hcyhlgp jdryjxj
3 Aug 23
Regeneron Reports Second Quarter 2023 Financial and Operating Results
6:48am
8-K
EX-99.1
4rlpc94ugetj
4 May 23
Regeneron Reports First Quarter 2023 Financial and Operating Results
7:11am
8-K
EX-99.1
pwwcg09rkz
3 Nov 22
Regeneron Reports Third Quarter 2022 Financial and Operating Results
7:19am
CORRESP
va2xtro 7b9zsils9a8
7 Oct 22
Correspondence with SEC
12:00am
UPLOAD
v1xrs180lpo59v
21 Sep 22
Letter from SEC
12:00am